4-Me-αMT (developmental code name MP-809), or 4-Me-AMT, also known as 4-methyl-α-methyltryptamine or as 4,α-dimethyltryptamine (4,α-DMT), is an experimental antidepressant of the tryptamine and α-alkyltryptamine families that was never marketed. It is closely structurally related to serotonergic psychedelics and entactogens like α-methyltryptamine (αMT) and α-ethyltryptamine (αET).
4-Me-αMT (developmental code name MP-809), or 4-Me-AMT, also known as 4-methyl-α-methyltryptamine or as 4,α-dimethyltryptamine (4,α-DMT), is an experimental antidepressant of the tryptamine and α-alkyltryptamine families that was never marketed. It is closely structurally related to serotonergic psychedelics and entactogens like α-methyltryptamine (αMT) and α-ethyltryptamine (αET).
==Use and effects== 4-Me-αMT is active at a dose of 20 to 60mg orally in humans, though described as being an antidepressant rather than a hallucinogen. It was found to be effective as an antidepressant in preliminary clinical studies. Alexander Shulgin has said that 4-Me-αMT produced some feelings of unreality at 20mg, as well as skin flushing, muscle tightness, and mydriasis. However, he has said that it could not be called a hallucinogen at assessed doses and has listed the hallucinogenic dose as being greater than 60mg.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).